The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines

Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe t...

Descripción completa

Detalles Bibliográficos
Autores principales: Condit, Richard C, Kim, Denny, Robertson, James S., Excler, Jean-Louis, Gurwith, Marc, Monath, Thomas P., Pavlakis, George, Fast, Patricia E., Smith, Jonathan, Smith, Emily R., Chen, Robert T., Kochhar, Sonali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474958/
https://www.ncbi.nlm.nih.gov/pubmed/32907759
http://dx.doi.org/10.1016/j.vaccine.2020.08.009
_version_ 1783579424675856384
author Condit, Richard C
Kim, Denny
Robertson, James S.
Excler, Jean-Louis
Gurwith, Marc
Monath, Thomas P.
Pavlakis, George
Fast, Patricia E.
Smith, Jonathan
Smith, Emily R.
Chen, Robert T.
Kochhar, Sonali
author_facet Condit, Richard C
Kim, Denny
Robertson, James S.
Excler, Jean-Louis
Gurwith, Marc
Monath, Thomas P.
Pavlakis, George
Fast, Patricia E.
Smith, Jonathan
Smith, Emily R.
Chen, Robert T.
Kochhar, Sonali
author_sort Condit, Richard C
collection PubMed
description Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. This will facilitate key stakeholders to anticipate potential safety issues and interpret or assess safety data. This would also help improve communication and public acceptance of licensed viral vector vaccines.
format Online
Article
Text
id pubmed-7474958
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-74749582020-09-08 The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines Condit, Richard C Kim, Denny Robertson, James S. Excler, Jean-Louis Gurwith, Marc Monath, Thomas P. Pavlakis, George Fast, Patricia E. Smith, Jonathan Smith, Emily R. Chen, Robert T. Kochhar, Sonali Vaccine Review Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. This will facilitate key stakeholders to anticipate potential safety issues and interpret or assess safety data. This would also help improve communication and public acceptance of licensed viral vector vaccines. The Author(s). Published by Elsevier Ltd. 2020-11-17 2020-09-06 /pmc/articles/PMC7474958/ /pubmed/32907759 http://dx.doi.org/10.1016/j.vaccine.2020.08.009 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Condit, Richard C
Kim, Denny
Robertson, James S.
Excler, Jean-Louis
Gurwith, Marc
Monath, Thomas P.
Pavlakis, George
Fast, Patricia E.
Smith, Jonathan
Smith, Emily R.
Chen, Robert T.
Kochhar, Sonali
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
title The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
title_full The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
title_fullStr The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
title_full_unstemmed The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
title_short The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
title_sort brighton collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474958/
https://www.ncbi.nlm.nih.gov/pubmed/32907759
http://dx.doi.org/10.1016/j.vaccine.2020.08.009
work_keys_str_mv AT conditrichardc thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT kimdenny thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT robertsonjamess thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT exclerjeanlouis thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT gurwithmarc thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT monaththomasp thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT pavlakisgeorge thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT fastpatriciae thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT smithjonathan thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT smithemilyr thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT chenrobertt thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT kochharsonali thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT thebrightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT conditrichardc brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT kimdenny brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT robertsonjamess brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT exclerjeanlouis brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT gurwithmarc brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT monaththomasp brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT pavlakisgeorge brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT fastpatriciae brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT smithjonathan brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT smithemilyr brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT chenrobertt brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT kochharsonali brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines
AT brightoncollaborationstandardizedtemplateforcollectionofkeyinformationforbenefitriskassessmentofviralvectorvaccines

Ejemplares similares